PL1948789T3 - Sposób wytwarzania ciągłych ludzkich linii komórkowych - Google Patents

Sposób wytwarzania ciągłych ludzkich linii komórkowych

Info

Publication number
PL1948789T3
PL1948789T3 PL06818078T PL06818078T PL1948789T3 PL 1948789 T3 PL1948789 T3 PL 1948789T3 PL 06818078 T PL06818078 T PL 06818078T PL 06818078 T PL06818078 T PL 06818078T PL 1948789 T3 PL1948789 T3 PL 1948789T3
Authority
PL
Poland
Prior art keywords
production
human cell
cell lineages
permanent human
expression
Prior art date
Application number
PL06818078T
Other languages
English (en)
Inventor
Gudrun Schiedner
Christoph Volpers
Original Assignee
Cevec Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals Gmbh filed Critical Cevec Pharmaceuticals Gmbh
Publication of PL1948789T3 publication Critical patent/PL1948789T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0605Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0623Stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/04Immortalised cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/06Uses of viruses as vector in vitro

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
PL06818078T 2005-11-16 2006-11-15 Sposób wytwarzania ciągłych ludzkich linii komórkowych PL1948789T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005054628A DE102005054628A1 (de) 2005-11-16 2005-11-16 Verfahren zur Herstellung von permanenten humanen Zelllinien
EP06818078A EP1948789B1 (de) 2005-11-16 2006-11-15 Verfahren zur herstellung von permanenten humanen zelllinien
PCT/DE2006/002004 WO2007056994A2 (de) 2005-11-16 2006-11-15 Verfahren zur herstellung von permanenten humanen zelllinien

Publications (1)

Publication Number Publication Date
PL1948789T3 true PL1948789T3 (pl) 2010-11-30

Family

ID=37770340

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06818078T PL1948789T3 (pl) 2005-11-16 2006-11-15 Sposób wytwarzania ciągłych ludzkich linii komórkowych

Country Status (19)

Country Link
US (2) US8936908B2 (pl)
EP (1) EP1948789B1 (pl)
JP (1) JP5213719B2 (pl)
KR (1) KR101244529B1 (pl)
CN (1) CN101310014B (pl)
AT (1) ATE470702T1 (pl)
AU (1) AU2006314931B2 (pl)
CA (1) CA2629211C (pl)
CY (1) CY1110734T1 (pl)
DE (2) DE102005054628A1 (pl)
DK (1) DK1948789T3 (pl)
ES (1) ES2345508T3 (pl)
IL (1) IL190705A (pl)
MY (1) MY144034A (pl)
PL (1) PL1948789T3 (pl)
PT (1) PT1948789E (pl)
SG (1) SG173947A1 (pl)
SI (1) SI1948789T1 (pl)
WO (1) WO2007056994A2 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
DE102009003439A1 (de) * 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
CN101942413B (zh) * 2009-07-07 2015-02-11 翁炳焕 出生缺陷细胞库及其构建方法
EP2606128B1 (de) * 2010-08-16 2014-09-10 CEVEC Pharmaceuticals GmbH Permanente humane amniozyten zellinie zur herstellung von influenzaviren
EP2722337A1 (en) * 2012-10-19 2014-04-23 CEVEC Pharmaceuticals GmbH Production of a HCMV based vaccine in human amniocyte cell lines
EP2909228A1 (en) * 2012-10-19 2015-08-26 CEVEC Pharmaceuticals GmbH Production of a hcmv based vaccine in human amniocyte cell lines
RU2015135227A (ru) 2013-01-22 2018-12-25 Кенкор Биотех Лтд. Способ получения рекомбинантного человеческого протромбина и фибриногена
EP3154694B1 (en) 2014-06-13 2025-01-29 Children's Medical Center Corporation Products and methods to isolate mitochondria
JP6873917B2 (ja) * 2015-05-12 2021-05-19 サンガモ セラピューティクス, インコーポレイテッド ヌクレアーゼ介在性遺伝子発現調節
AU2016265845B2 (en) * 2015-05-15 2020-10-08 City Of Hope Chimeric antigen receptor compositions
EP3383411B1 (en) 2015-11-30 2025-07-09 Sana Biotechnology, Inc. Sub-mitochondrial particles for use in treating metabolic conditions
ES3057779T3 (en) 2016-01-15 2026-03-04 Childrens Medical Ct Corp Therapeutic use of mitochondria and combined mitochondrial agents
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
EP4017521A1 (en) 2019-09-02 2022-06-29 Biotest AG Factor viii protein with increased half-life
EP4106798A1 (en) 2020-02-17 2022-12-28 Biotest AG Subcutaneous administration of factor viii
EP4229204A1 (en) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Nucleic acid constructs for simultaneous gene activation
KR20230085929A (ko) 2020-10-15 2023-06-14 에프. 호프만-라 로슈 아게 Va rna 전사를 위한 핵산 구조체
CN118202060A (zh) 2021-10-05 2024-06-14 再生生物股份有限公司 用于重组aav生产的组合物和方法
WO2023060113A1 (en) 2021-10-05 2023-04-13 Regenxbio Inc. Compositions and methods for recombinant aav production
US12234472B2 (en) 2021-10-18 2025-02-25 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
CN119256220A (zh) 2022-05-23 2025-01-03 豪夫迈·罗氏有限公司 用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法
EP4532737A1 (en) 2022-06-03 2025-04-09 F. Hoffmann-La Roche AG Method for producing recombinant aav particles
KR20250036743A (ko) 2022-07-14 2025-03-14 에프. 호프만-라 로슈 아게 재조합 aav 입자를 생산하는 방법
EP4744752A1 (en) 2022-09-12 2026-05-20 Hoffmann La Roche METHOD FOR SEPARING SOLID AND EMPTY AAV PARTICLES
IL322001A (en) 2023-02-07 2025-09-01 Hoffmann La Roche Method for detecting antibodies to anti-AAV particles
EP4683676A1 (en) 2023-03-21 2026-01-28 F. Hoffmann-La Roche AG Method for the production of recombinant aav particle preparations
WO2025168663A1 (en) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna
WO2026022064A1 (en) 2024-07-22 2026-01-29 F. Hoffmann-La Roche Ag Novel aav rep orfs and rep polypeptides
WO2026037757A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Modified aav particles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797495B2 (en) * 1996-11-05 2004-09-28 The Regents Of The University Of California Somatic cells with ablated PrP gene and methods of use
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
CN100457914C (zh) 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6558948B1 (en) * 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
US6369448B1 (en) * 2000-01-21 2002-04-09 Lsi Logic Corporation Vertically integrated flip chip semiconductor package
EP2314629B2 (en) * 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
KR101183770B1 (ko) 2003-05-09 2012-09-17 크루셀 홀란드 비.브이. E1-불멸화된 세포의 배양물 및 이로부터 생성 수율을 증가시키기 위한 동일물의 배양 방법
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien

Also Published As

Publication number Publication date
CN101310014A (zh) 2008-11-19
WO2007056994A3 (de) 2007-11-01
US20070111312A1 (en) 2007-05-17
US9315773B2 (en) 2016-04-19
DE102005054628A1 (de) 2007-05-24
EP1948789B1 (de) 2010-06-09
KR101244529B1 (ko) 2013-03-18
DE502006007198D1 (de) 2010-07-22
IL190705A (en) 2012-04-30
JP2009515537A (ja) 2009-04-16
WO2007056994A8 (de) 2007-07-19
CA2629211A1 (en) 2007-05-24
SI1948789T1 (sl) 2010-08-31
MY144034A (en) 2011-07-29
CY1110734T1 (el) 2015-06-10
PT1948789E (pt) 2010-08-05
SG173947A1 (en) 2011-09-29
CN101310014B (zh) 2012-05-30
KR20090114306A (ko) 2009-11-03
DK1948789T3 (da) 2010-10-11
IL190705A0 (en) 2011-08-01
AU2006314931B2 (en) 2011-08-18
ES2345508T3 (es) 2010-09-24
US20150203813A1 (en) 2015-07-23
WO2007056994A2 (de) 2007-05-24
ATE470702T1 (de) 2010-06-15
AU2006314931A1 (en) 2007-05-24
JP5213719B2 (ja) 2013-06-19
US8936908B2 (en) 2015-01-20
EP1948789A2 (de) 2008-07-30
CA2629211C (en) 2016-05-10

Similar Documents

Publication Publication Date Title
SI1948789T1 (sl) Postopek za pridobivanje permanentnih humanih celičnih linij
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
MX2021015070A (es) Inmunomodulacion usando celulas madre de la placenta.
CA2782424C (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
MX2013004127A (es) Polipeptidos con actividad permeasa.
SG10201809901SA (en) Generating Pluripotent Cells De Novo
MY185887A (en) Cell culture improvements
WO2009149956A3 (en) Fusion protein and use thereof
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
EP2808393A3 (en) Fucosylation-deficient cells
MX2009011870A (es) Polipeptidos de interferon beta modificados y usos de los mismos.
WO2010078952A3 (de) Strukturierte gasdiffusionselektrode für elektrolysezellen
EP2516624A4 (en) CELL LINE 3M
WO2008114673A1 (ja) ポリペプチドの製造方法
WO2010111659A8 (en) Tumor-initiating cells and methods for using same
EP3078673A3 (en) Recombinant fibrinogen
PL1941027T3 (pl) Metody i środki do proliferacji komórek macierzystych oraz wytwarzania i ekspansji komórek progenitorowych, a także produkcji komórek efektorowych jako leków klinicznych
WO2007003582A3 (en) Serum-free stable transfection and production of recombinant human proteins in human cell lines
MX2011012623A (es) Construcciones de casb7439.
GB0410130D0 (en) Cell preparation
MX2010005716A (es) Polinucleotidos y metodos para mejorar plantas.
WO2012012271A3 (en) Novel glycosylated polypeptides
WO2009004664A8 (en) Immortalized cell line of murine mesenchymal stem cells, method for preparation and uses thereof
HK40062420A (en) Novel selection marker-comprising cell line and uses thereof for protein production
WO2008147426A3 (en) Methods and compositions for immunomodulation